Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
LTR Pharma Limited ( (AU:LTP) ) has provided an update.
LTR Pharma Limited has surpassed 1,000 prescriptions of its SPONTAN® product under Australia’s TGA Special Access Scheme, reflecting growing clinical demand for alternative erectile dysfunction treatments. This milestone provides valuable real-world insights that inform LTR’s commercial strategy, particularly as it prepares for the US launch of ROXUS® in 2026, and highlights the company’s expanding influence in addressing unmet medical needs.
More about LTR Pharma Limited
LTR Pharma is a commercial-stage pharmaceutical company focused on delivering innovative therapies through its proprietary intranasal drug-delivery platform. The company has commercialized rapid-acting treatment technology in Australia and is expanding its reach in the US and other key markets. LTR’s lead products include SPONTAN® and ROXUS®, fast-acting intranasal sprays for erectile dysfunction, and it is developing OROFLOW® for Oesophageal Motility Disorders.
Average Trading Volume: 476,891
Technical Sentiment Signal: Sell
Current Market Cap: A$91.73M
Find detailed analytics on LTP stock on TipRanks’ Stock Analysis page.